SA

Sangita Atul Girme

Director Director DIN 06499002
DIN 06499002 First appointment Feb 2013 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Past companies 2 historical roles
Total affiliations 2 Since Feb 2013
Shareholding value β€’β€’β€’β€’ Premium profile

About Sangita Atul Girme

Data last updated:

Sangita Atul Girme was a Director at Rich Pharma India Private Limited (2013–2016) and Designated Partner at Health Chemist Llp (2018). The companies operate in Pharma.

DIN 06499002
Primary Designation Director
Industry Pharma
First Appointment 15 Feb 2013

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Rich Pharma India Private Limited U24239PN2008PTC131753
Director15 Feb 20132008₹5.10 Cr (FY 2016)Active
Designated Partner27 Jul 20182018Strike Off

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Rich Pharma India Private Limited
Health Chemist Llp
Premium access

Shareholding and investment profile for Sangita Atul Girme

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Sangita Atul Girme

Sangita Atul Girme was first appointed on 15 Feb 2013 as Director at Rich Pharma India Private Limited. The most recent appointment on record is 27 Jul 2018 at Health Chemist Llp.

Sangita Atul Girme held 2 earlier board appointments: Rich Pharma India Private Limited (Director, 15 Feb 2013 to 20 May 2016); Health Chemist Llp (Designated Partner, 27 Jul 2018 to 31 Oct 2018).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available